RT Journal Article SR Electronic T1 JNMT continuing education: 177Lu PSMA therapy JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP jnmt.122.263814 DO 10.2967/jnmt.122.263814 A1 Ephraim E Parent A1 Bital Savir-Baruch A1 Isis W Gayed A1 Frankis Almaguel A1 Bennett Chin A1 Austin R Pantel A1 Evan Armstrong A1 Amanda Morley A1 Robin C Ippisch A1 Robert Richard Flavell YR 2022 UL http://tech.snmjournals.org/content/early/2022/07/26/jnmt.122.263814.abstract AB Radiopharmaceutical therapy utilizing 177Lu-PSMA is an effective treatment for prostate cancer which has recently been approved by the United States Food and Drug Administration. This method leverages the success of PSMA targeted PET imaging, enabling the delivery of targeted radiopharmaceutical therapy, This agent has demonstrated a clear benefit in large prospective clinical trials, and promises to become part of the standard armamentarium of treatment for patients with prostate cancer. In this review, the evidence supporting the use of this agent is highlighted, along with important areas now under investigation. Practical information on technology aspects, dose administration, nursing, and the role of the treating physician is highlighted. Overall, 177Lu-PSMA treatment requires close collaboration between referring physicians, nuclear medicine, technologists, radiopharmacy, and nursing, to enable streamlined patient care.